NCT06157086Active, not recruiting
Assessment of the Quality of Life of Multiple Sclerosis Patients Treated With Ofatumumab in Real-life in France
This is a Non-interventional, Prospective, Multicenter Study Conducted in France. The Primary Objective of This Study is to Describe the Quality of Life of MS Patients After Initiation of Treatment With Ofatumumab.
Source: ClinicalTrials.gov · Last updated 29 Apr 2026
Brief summary (registry, in English)
SEPROS is a non-interventional study, based on primary data collection of MS adult patients who initiated ofatumumab as per neurologist practice and regardless of the study protocol.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 302 (actual)
- First submitted
- 27 Nov 2023
- Start date
- 21 Dec 2023
- Primary completion date
- 31 Jul 2026
- Lead sponsor
- Novartis Pharmaceuticals
- Diseases
- Multiple sclerosis
- NCT number
- NCT06157086
What you commit to
- Study type: Observational
- Participants enrolled: 302
- From 21 Dec 2023 to the primary completion date, 31 Jul 2026
- 45 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- 1\. Patient treated with ofatumumab in the context of a clinical trial
Who the study is looking for
- Male or female, 18 years of age or older
- Patient with confirmed MS diagnosis
- Patient initiating treatment with ofatumumab for the first time
- Patient for which the decision to initiate treatment with ofatumumab was made by the doctor (investigator) in accordance with his/her usual practices independently of the study
- Patient not opposed to participation in this study
- Patient willing and able to complete patient questionnaires
Age in the registry: 18 years to 99 years · Sex: All · Does not accept healthy volunteers
Sites (45)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.